Germany· DE-A57-304ee4095d213fcf
Aralia
A medicinal product containing allium cepa dil. d 3, aralia racemosa dil. d2, euphrasia 3c d6, schoenocaulon officinale d8, acidum silicicum dil. d8, registered in Germany by Nestmann Pharma Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Allium Cepa Dil. D 3, Aralia Racemosa Dil. D2, Euphrasia 3c D6, Schoenocaulon Officinale D8, Acidum Silicicum Dil. D8
- Manufacturer
- Nestmann Pharma Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f015670f-d5e4-4146-87dd-c75d906f4088 GET /v1/drugs/f015670f-d5e4-4146-87dd-c75d906f4088?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Allium Cepa Dil. D 3, Aralia Racemosa Dil. D2, Euphrasia 3c D6, Schoenocaulon Officinale D8, Acidum Silicicum Dil. D8",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about allium cepa dil. d 3, aralia racemosa dil. d2, euphrasia 3c d6, schoenocaulon officinale d8, acidum silicicum dil. d8.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.